WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 27, 2024--
Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March:
-
TD Cowen 44th Annual Health Care Conference being held in Boston on March 4 – 6
-
Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13
The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.
About Tectonic Therapeutic
Tectonic Therapeutic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting GPCRs to develop novel therapies for patients inadequately served by current treatments. With its proprietary GEODe™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class, where small molecule pharmacology may be intractable. In February 2024, Tectonic entered into a definitive agreement to merge with AVROBIO, Inc. (Nasdaq: AVRO). Tectonic is headquartered in Watertown, Massachusetts. Learn more at www.tectonictx.com and follow us @TectonicTx.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20240227911667/en/
Tectonic Therapeutic Contacts:
Investors:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Media:
Karen Sharma
MacDougall
ksharma@macdougall.bio
(781) 235-3060
Source: Tectonic Therapeutic, Inc.
